Teewinot collects patents to make cannabinoids in US and Ireland

By Flora Southey contact

- Last updated on GMT

GettyImages/Shidlovski
GettyImages/Shidlovski

Related tags: United states patent and trademark office, Us

The US State Patent and Trademark Office has granted Teewinot Life Science Corporation its second patent this year covering biosynthetic cannabinoid production methods.

The firm’s Irish subsidiary Teewinot Technologies – formerly Full Spectrum Laboratories – announced the US State Patent and Trademark Office (USPTO) had granted Patent No. 9,879,292​, earlier this week.

Patent ‘292 covers the firm’s synthetic biology approach to making tetrahydrocannabinolic acid (THCA), cannabichromenic acid (CBCA) and cannabichromenic acid (CBCA) in different ratios for cannabinoids and cannabinoid analogs.

This is the second US patent granted to Teewinot in 2018.

Last month, Teewinot announced the USPTO had granted Patent No. 9,861,609​ covering methods for producing cannabinoids and cannabinoid analogs, as well as a system for producing these compounds.

Biosynthetic cannabinoids

Executive vice president Richard Peet told us these additional patents bring the firms’ US count to seven with claims directed to the manufacture of biosynthetic cannabinoids.

Teewinot’s biosynthetic processes use genes cloned from the cannabis plant that code for enzymes, to make cannabinoids, Peet told us.

“We make the cannabinoids in yeast or other microorganisms – using synthetic biology or by means of biocatalysis – and can now make 18 different naturally occurring cannabinoids,” ​he added.

Peet said these cannabinoids have the exact same stereochemical structure as cannabinoids produced in cannabis.

Teewinot has similarly filed these patents globally, including in Europe, Canada, Japan and China.

Manufacturing

Peet said Teewinot is looking to manufacture in the US and Ireland, before conducting in-house clinical trials.

The firm has collaborated with contract manufacturing organisation (CMO) Albany Molecular (AMRI) in New York state to make cannabinoids in the US.

Teewinot also plans to manufacture in the Ireland, but did not disclose the partnering CMO.

“We may use a contract research organisation (CRO) for some of the preclinical trials, but we’ll be doing the clinical trials ourselves,” ​he said.

Teewinot is open to collaborating with drug firms, said Peet: “We are looking for pharmaceutical companies that are interested in partnering with us, to take one or more of our molecules forward.”​  

Related news

Show more

Related products

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Related suppliers

Follow us

Products

View more

Webinars